- Journal List
- Springer
- PMC11101533
As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsem*nt of, or agreement with, the contents by NLM or the National Institutes of Health.
Learn more: PMC Disclaimer | PMC Copyright Notice
Breast Cancer Res Treat. 2024; 205(3): 609–618.
Published online 2024 Mar 22. doi:10.1007/s10549-024-07279-w
PMCID: PMC11101533
PMID: 38517602
Lindsay J. Collin,
1 Jade Jones,2 Rebecca Nash,3 Jeffrey M. Switchenko,4 Kevin C. Ward,3 and Lauren E. McCullough3
Author information Article notes Copyright and License information PMC Disclaimer
Associated Data
- Supplementary Materials
- Data Availability Statement
Abstract
Purpose
The majority of breast cancer patients are diagnosed with early-stage estrogen receptor (ER) positive disease. Despite effective treatments for these cancers, Black women have higher mortality than White women. We investigated demographic and clinical factors associated with receipt of chemotherapy among those with a discretionary indication who are at risk for overtreatment.
Methods
Using Georgia Cancer Registry data, we identified females diagnosed with ER positive breast cancer who had a discretionary indication for chemotherapy (2010–2017). We used logistic regression to estimate odds ratios (ORs) and 95% confidence intervals (CIs) associating patient demographic and clinical characteristics with chemotherapy initiation overall, and comparing non-Hispanic Black (NHB) with non-Hispanic White (NHW) women within strata of patient factors.
Results
We identified 11,993 ER positive breast cancer patients with a discretionary indication for chemotherapy. NHB patients were more likely to initiate chemotherapy compared with NHW women (OR = 1.41, 95% CI: 1.28, 1.56). Race differences in chemotherapy initiation were pronounced among those who did not receive Oncotype DX testing (OR = 1.47, 95% CI: 1.31, 1.65) and among those residing in high socioeconomic status neighborhoods (OR = 2.48, 95% CI: 1.70, 3.61). However, we observed equitable chemotherapy receipt among patients who received Oncotype DX testing (OR = 0.90, 95% CI: 0.71, 1.14), were diagnosed with grade 1 disease (OR = 1.00, 95% CI: 0.74, 1.37), and those resided in rural areas (OR = 1.01, 95% CI: 0.76, 1.36).
Conclusion
We observed racial disparities in the initiation of chemotherapy overall and by sociodemographic and clinical factors, and more equitable outcomes when clinical guidelines were followed.
Supplementary Information
The online version contains supplementary material available at 10.1007/s10549-024-07279-w.
Keywords: Breast cancer, Cancer health disparities, Survivorship, Chemotherapy
Introduction
Breast cancer is the most commonly diagnosed cancer among women in the United States (US) and the second leading cause of cancer-specific mortality despite a high five-year relative survival of approximately 90% [1–3]. The majority of breast cancer patients present with early-stage (91%), estrogen receptor (ER) positive disease (~ 75%), and/or no lymph node involvement (~ 65%) at diagnosis, which also contribute to the overall favorable prognosis [3–5]. Among breast cancer patients diagnosed with ER-positive disease and no lymph node involvement, chemotherapy may be considered a discretionary treatment according to the National Comprehensive Cancer Network (NCCN) clinical guidelines [6]. Chemotherapy can have severe side effects that impact quality of life [6], including neuropathy, cognitive impairment (i.e., “chemo brain”), neutropenia, infections, and other poor patient-reported outcomes. Therefore, ensuring that unnecessary chemotherapy is avoided is critical to improving quality of life for breast cancer survivors.
Black women in the US experience persistent disparities in breast cancer mortality compared with White women [7–10]. Notably, these racial disparities in mortality are most pronounced for breast cancers with effective treatment regimens [11]. Our group has previously reported that Black and White women in the metropolitan Atlanta area diagnosed with nonmetastatic breast cancer were equally likely to receive guideline-concordant care [5]. However, Black women were more likely to receive chemotherapy than White women, with the most notable discrepancies in receipt of chemotherapy among patients with a discretionary indication for chemotherapy [5]. Previous studies have suggested that Black women are more likely to receive chemotherapy than other racial and ethnic groups, which may lead to overtreatment among Black women expected to have a favorable prognosis [12, 13]. In instances when chemotherapy is considered discretionary, Black women may be more likely to receive therapy due to the concern that their outcomes (i.e., recurrence or mortality) are often worse than other racial and ethnic groups. However, the decision-making process on care protocols must also weigh the concerns of overtreatment due to the negative side effects of chemotherapy [10]. A previous study of breast cancer patients reported that receipt of chemotherapy among women with a discretionary indication for chemotherapy was associated with clinical predictors of poor outcomes [14]. This study did not find differences in the initiation of chemotherapy by race, but was limited in the approach due to a small number of Black women (n = 61) and it did not examine differences in chemotherapy initiation across patient characteristics [14].
We sought to understand patient demographic and clinical factors associated with the receipt of chemotherapy among women with a discretionary indication for chemotherapy who may be at risk for overtreatment. We examined potential race differences in chemotherapy initiation among non-Hispanic Black (NHB) and non-Hispanic White (NHW) women overall and across strata of important demographic and clinical factors.
Methods
Study population
Using the Georgia Cancer Registry (GCR), we identified women diagnosed with breast cancer between 2010 and 2017 while residing in the state of Georgia. Breast cancer patients were included if they were diagnosed with an invasive first primary ER-positive breast tumor and were classified as being NHB or NHW [15]. Race is a social construct, representing the social and structural interactions to maintain the privilege, power, and resource aggregation of the dominant group. Therefore, throughout this manuscript, we evaluated potential racial disparities in chemotherapy receipt among breast cancer patients. We identified ER positive breast cancer patients at risk for overtreatment, including women who were considered discretionary for chemotherapy according to the 2016 NCCN guidelines (Supplemental Table1) [6, 16]. These included patients diagnosed with: (1) ER-positive/HER2-positive breast cancer with no lymph node involvement and tumor size ≤ 1.0cm, and (2) ER-positive/HER2-negative breast cancer with no lymph node involvement and tumor size > 0.5cm–5cm, who received an Oncotype DX recurrence score of Intermediate (18–30), or (3) ER-positive/HER2-negative breast cancer with no lymph node involvement and tumor size > 0.5cm–5cm, who did not receive Oncotype DX testing.
In an additional analysis, we identified women for which chemotherapy is indicated, but they had limited lymph node involvement (1–3 positive nodes) [6, 16]. We included this analysis because we previously observed that NHB breast cancer patients were more likely to initiate chemotherapy than NHW patients in this subset of patients [5].
Outcome assessment
The primary outcome of interest was chemotherapy initiation. Initiation of chemotherapy was available from the GCR and was coded as yes or no. The GCR collects information on first-line therapies received as well as their dates of initiation. We defined chemotherapy initiation as receipt of chemotherapy following breast cancer diagnosis in our study. However, systemic therapies are incompletely captured in cancer registries and “no” can both refer to not receiving chemotherapy or unknown receipt of chemotherapy. Our secondary outcome of interest was breast cancer-specific mortality. Breast cancer mortality (ICD10-C50) was determined from death certificate data. Follow-up was defined as time in months, from the date of diagnosis until the first of a) death, b) last date of contact in the registry, or c) December 31, 2019, the end of study follow-up.
Patient demographic and clinical characteristics
We collected information on patient demographic and clinical characteristics that may influence initiation of chemotherapy. These clinical factors included age at diagnosis (years, continuous), tumor stage (I–III), tumor grade (1, 2, 3 +), tumor size (cm), number of positive lymph nodes (0, 1, 2, 3), and receipt of Oncotype DX testing (yes, no). We also collected demographic characteristics including race and ethnicity (NHB, NHW), marital status (single, married/domestic partner, divorced/separated/other), insurance status (private, Medicare, Medicaid, military/other, and uninsured), urban or rural residence, and a Census-derived area-based measure of socioeconomic status [SES] (0%– < 5%, 5%– < 10%, 10%– < 20%, 20%–100% below poverty). SES was based on Census tract-level poverty data published annually from the American Community Survey [17, 18].
Statistical methods
Descriptive statistics were calculated as median values and interquartile range (IQR) or frequency and percent for covariates of interest across categories of chemotherapy initiation. We used multivariable-adjusted logistic regression models to compute the odds ratios (OR) and 95% confidence intervals (CI) associating patient demographic and clinical characteristics with the initiation of chemotherapy. We further computed racial disparities in receipt of chemotherapy, and whether clinical and patient demographic characteristics modified these associations by comparing stratum-specific estimates of association. We also explored the associations of clinical and patient demographic characteristics with initiation of chemotherapy by age (< 55years, ≥ 55years). We did this because women diagnosed with breast cancer at a younger age may be treated more aggressively than women diagnosed later in life and, therefore, may be more likely to receive chemotherapy. In an additional analysis, we examined associations of sociodemographic and clinical characteristics with chemotherapy initiation among breast cancer patients diagnosed with ER-positive disease and limited lymph node involvement (Supplemental Tables2, 3, and 4).
We then examined racial disparities in breast cancer mortality within strata of chemotherapy initiation by using Cox proportional hazards regression to compute the hazard ratios (HR) and 95% CIs. Due to confounding by indication [19], we could not reliably compute overall estimates for the association between chemotherapy initiation and breast cancer mortality and therefore only present racial disparities in breast cancer mortality within stratum of chemotherapy initiation. The proportional hazards assumption was assessed by visual inspection of the ln-ln survival curves.
For all models, we assessed confounding based on a priori knowledge and graphical-based methods (DAGs) [20]. For the associations of patient demographic and clinical characteristics with chemotherapy initiation, potential confounders included age at diagnosis, tumor stage, tumor grade, SES, insurance status, and marital status. In the models examining racial disparities in breast cancer mortality, we present age-adjusted analyses for the racial disparity as well as multivariable-adjusted models, including age, stage, grade, insurance status, SES, receipt of Oncotype DX testing, marital status, and urban/rural geography. No hypothesis testing was performed [21, 22]. All analyses were conducted using SAS v9.4 (Cary, NC).
Results
The study cohort included 11,993 breast cancer patients with ER-positive disease and a discretionary indication for chemotherapy of which 2,882 (24%) were NHB and 9,111 (76%) were NHW (Table1). The distribution of discretionary groups from Table1 were comparable across NHW and NHB patients (ER + /HER2 + : 5.7%, 6.9%; ER + /HER2 − and Oncotype DX Intermediate: 16%, 16%; ER + /HER2 − no Oncotype DX testing: 78%, 77%, respectively; data not shown). In Table1 we compare the distribution of patient demographic and clinical characteristics among those who did and did not receive chemotherapy. In this cohort, 2,872 (24%) initiated chemotherapy. NHB women were more likely to initiate chemotherapy than NHW women (33% vs. 21%). Breast cancer patients who initiated chemotherapy were 55years of age on average (IQR: 46, 63years) compared with 66years of age among those who did not initiate chemotherapy (IQR: 58, 74). Breast cancer patients who were single at the time of diagnosis were more likely to initiate chemotherapy than those who were married at the time of diagnosis (34% vs. 26%, respectively). As expected, patients diagnosed with more aggressive disease (i.e., later stage, higher grade, and larger tumor size) were more likely to receive chemotherapy. Initiation of chemotherapy did not vary by socioeconomic index or urban/rural residency. Individuals who had Medicaid insurance were more likely to initiate chemotherapy compared with those who had Medicare insurance (42% vs. 11%).
Table1
Demographic, tumor, and patient characteristics by receipt of chemotherapy among 11,993 non-Hispanic Black (NHB) and non-Hispanic White (NHW) women diagnosed with ER + breast cancer and discretionary indication for chemotherapy diagnosed in Georgia (2010–2017)
| Chemotherapy initiation | ||||
|---|---|---|---|---|
| Yes | No | |||
| (n = 2,872) | (n = 9,121) | |||
| Median | IQR | Median | IQR | |
| Age at diagnosis (years) | 55 | 46, 63 | 66 | 58, 74 |
| Length of follow-up (months) | 67 | 44, 92 | 56 | 39, 84 |
| N | % | N | % | |
| Breast cancer-specific death | 165 | 5.8 | 21 | 2.4 |
| Race and ethnicity | ||||
| NHB | 942 | 33 | 1940 | 67 |
| NHW | 1930 | 21 | 7181 | 79 |
| Age at diagnosis | ||||
| > 70 | 182 | 5.3 | 3268 | 95 |
| 55–70 | 1180 | 23 | 3997 | 77 |
| ≤ 55 | 1510 | 45 | 1856 | 55 |
| Stage | ||||
| I | 1717 | 19 | 7512 | 81 |
| II | 1155 | 42 | 1609 | 58 |
| Tumor grade | ||||
| 1 | 286 | 7.6 | 3498 | 92 |
| 2 | 1145 | 21 | 4380 | 79 |
| 3 + | 1395 | 57 | 1061 | 43 |
| Unknown | 46 | 20 | 182 | 80 |
| Tumor size (cm) | ||||
| ≤ 0.5 | 76 | 26 | 222 | 74 |
| 0.6–1 | 615 | 16 | 3251 | 84 |
| > 1 to < 5 | 2181 | 29 | 5648 | 72 |
| Unknown | ||||
| ODX testing | ||||
| Not performed | 2228 | 22 | 7794 | 78 |
| Performed | 644 | 33 | 1327 | 67 |
| Subtype | ||||
| ER + /HER2- | 2539 | 23 | 8744 | 77 |
| ER + /HER2 + | 333 | 47 | 377 | 53 |
| Demographic characteristics | ||||
| Marital status | ||||
| Single | 469 | 34 | 921 | 66 |
| Married (common law and unmarried domestic) | 1719 | 26 | 4826 | 74 |
| Other (divorced, widowed, separated) | 575 | 16 | 2957 | 84 |
| Unknown | 109 | 21 | 417 | 79 |
| Socioeconomic Index | ||||
| 0% – < 5% poverty | 392 | 23 | 1340 | 77 |
| 5% – < 10% poverty | 581 | 22 | 2017 | 78 |
| 10% – < 20% poverty | 1037 | 25 | 3088 | 75 |
| 20–100% poverty | 862 | 24 | 2676 | 76 |
| Urban/rural residence | ||||
| Urban | 2382 | 24 | 7374 | 76 |
| Rural | 489 | 22 | 1747 | 78 |
| Insurance type | ||||
| Uninsured | 40 | 33 | 82 | 67 |
| Private | 1896 | 34 | 3665 | 66 |
| Medicaid | 238 | 42 | 335 | 58 |
| Medicare | 584 | 11 | 4749 | 89 |
| Military | 71 | 32 | 151 | 68 |
| Unknown | 42 | 23 | 138 | 77 |
Open in a separate window
In Table2 we present the multivariable-adjusted associations relating clinical and patient demographic characteristics with receipt of chemotherapy. Among all women who were discretionary for chemotherapy, breast cancer patients who were > 70years at diagnosis had lower odds of receiving chemotherapy (OR = 0.72, 95% CI: 0.52, 0.98) than those who were ≤ 55years at diagnosis. However, breast cancer patients who were 56–70years at diagnosis had higher odds of receiving chemotherapy than those who were ≤ 55years at diagnosis (OR = 1.28, 95% CI: 1.08, 1.51). As expected, increasing stage and grade were associated with an increased odds of receipt of chemotherapy. Interestingly, those who did not receive Oncotype DX testing had lower odds of receiving chemotherapy (OR = 0.77, 95% CI: 0.69, 0.87) than those who received an Oncotype DX test. Breast cancer patients residing in neighborhoods with low SES had 1.3-times to the odds of receiving chemotherapy than those who lived in high SES neighborhoods (OR = 1.35, 95% CI: 1.15, 1.58). We did not observe a difference in chemotherapy initiation by urbanicity (OR = 0.95, 95% CI: 0.83, 1.08). Breast cancer patients with Medicaid insurance had higher odds of receiving chemotherapy than those with private insurance (OR = 1.25, 95% CI: 1.03, 1.53).
Table2
Multivariable-adjusted odds ratios and 95% confidence intervals associating patient demographic, tumor characteristics with receipt of chemotherapy, and racial disparities in those associations among breast cancer patients with discretionary indication for chemotherapy in Georgia (2010–2017)
| Discretionary indication for chemotherapy | |||||
|---|---|---|---|---|---|
| Patient demographic and tumor characteristics | (N) | Overall OR (95% CI)a | Treatment (N) | Stratified OR (95% CI)a | |
| Overall | NHW | NHB | |||
| Overall disparity | 2,872 | – | 1930 | 942 | 1.41 (1.28, 1.56) |
| Age at diagnosis | |||||
| > 70 | 182 | 0.72 (0.52, 0.98) | 143 | 39 | 1.32 (0.92, 1.61) |
| 55–70 | 1180 | 1.28 (1.08, 1.51) | 845 | 335 | 1.33 (1.15, 1.55) |
| ≤ 55 | 1510 | Ref | 942 | 568 | 1.51 (1.30, 1.75) |
| Stage | |||||
| I | 1717 | Ref | 1,202 | 515 | 1.30 (1.14, 1.48) |
| II | 1155 | 3.27 (2.95, 3.63) | 728 | 427 | 1.38 (1.15, 1.66) |
| Tumor grade | |||||
| 1 | 286 | Ref | 225 | 61 | 1.00 (0.74, 1.37) |
| 2 | 1145 | 3.16 (2.74, 3.65) | 836 | 309 | 1.04 (0.89, 1.23) |
| 3 + | 1395 | 15 (3, 18) | 837 | 558 | 1.15 (0.96, 1.40) |
| ODX testing | |||||
| Testing not performed | 2228 | 0.77 (0.69, 0.87) | 1448 | 780 | 1.47 (1.31, 1.65) |
| Scored | 644 | Ref | 482 | 162 | 0.90 (0.71, 1.14) |
| Marital status | |||||
| Single | 1041 | 1.00 (0.91, 1.10) | 543 | 498 | 1.37 (1.18, 1.60) |
| Married | 1722 | Ref | 1324 | 398 | 1.50 (1.29, 1.74) |
| Socioeconomic Index | |||||
| 0% – < 5% poverty | 392 | Ref | 324 | 68 | 2.48 (1.70, 3.61) |
| 5% – < 10% poverty | 581 | 0.99 (0.84, 1.16) | 447 | 134 | 1.46 (1.13, 1.88) |
| 10% – < 20% poverty | 1037 | 1.26 (1.09, 1.47) | 681 | 356 | 1.40 (1.18, 1.67) |
| 20–100% poverty | 862 | 1.35 (1.15, 1.58) | 478 | 384 | 1.16 (0.97, 1.39) |
| Urban/rural residence | |||||
| Urban | 2382 | Ref | 1642 | 988 | 1.32 (0.91, 1.23) |
| Rural | 489 | 0.95 (0.83, 1.08) | 444 | 106 | 1.01 (0.76, 1.36) |
| Insurance type | |||||
| Uninsured | 40 | 0.97 (0.64, 1.47) | 22 | 22 | 1.12 (0.48, 2.63) |
| Private | 1896 | Ref | 1392 | 683 | 1.44 (1.25, 1.65) |
| Medicaid | 238 | 1.25 (1.03, 1.53) | 129 | 156 | 1.15 (0.80, 1.66) |
| Medicare | 584 | 0.80 (0.70, 0.92) | 472 | 181 | 1.33 (1.08, 1.64) |
| Military | 71 | 1.01 (0.74, 1.37) | 39 | 42 | 1.37 (0.73, 2.55) |
Open in a separate window
aAdjusted for: age, stage, grade, insurance status, poverty level, receipt of Oncotype DX, marital status, urban/rural
Table Table22 also shows estimates for racial disparities (NHB vs NHW) in receipt of chemotherapy within strata of patient characteristics. Overall, we observed a racial disparity in chemotherapy initiation in our study—NHB women had 1.41-times to the odds of receiving chemotherapy (95% CI: 1.28, 1.56) than NHW women. However, the magnitude of the disparity varied across patient demographic and clinical characteristics. Among breast cancer patients who were ≤ 55years at diagnosis, NHB women had 1.51 times the odds of receiving chemotherapy compared with NHW women (95% CI: 1.30, 1.75), whereas among women > 70 at diagnosis the disparity estimate was attenuated (OR = 1.32, 95% CI: 0.92, 1.61). Among breast cancer patients diagnosed with grade 1 tumors we did not observe a difference in receipt of chemotherapy between NHB and NHW women (OR = 1.00, 95% CI: 0.74, 1.37); however, with an increase in the tumor grade, NHB women had higher odds of receiving chemotherapy compared with NHW women. NHB women who did not receive Oncotype DX testing had 1.47 times the odds of receiving chemotherapy than NHW women (OR = 1.47, 95% CI: 1.31, 1.65); however, NHB women who received Oncotype DX testing had slightly lower odds of receiving chemotherapy than NHW women (OR = 0.90, 95% CI: 0.71, 1.14). The most pronounced disparity was observed among women residing in neighborhoods with the lowest proportion of residents living below the poverty index (OR = 2.48, 95% CI: 1.70, 3.61). Similarly, NHB women residing in urban settings had 1.32 times the odds of initiating chemotherapy than NHW women (OR = 1.32, 95% CI: 0.91, 1.23), whereas we did not observe a disparity among those residing in rural areas (OR = 1.01, 95% CI: 0.76, 1.36).NHB women with private insurance or Medicare had higher odds of initiating chemotherapy compared with NHW women (OR = 1.44, 95% CI: 1.25, 1.65 and OR = 1.33, 95% CI: 1.08, 1.64, respectively).
We additionally stratified the discretionary cohort by age at diagnosis (≥ 55years vs. < 55years) to investigate if the racial disparity we observed in the initiation of chemotherapy was driven by the on average younger age of diagnosis on average among NHB women (Table3). We generally observed consistent estimates of association across the sociodemographic and clinical factors, as well as in the estimates on racial disparities in chemotherapy initiation. One exception was in tumor grade. Among those diagnosed < 55years of age, NHB women had higher odds of initiating chemotherapy than NHW women among those diagnosed with grade 1 (OR = 1.53, 95% CI: 0.99, 2.35). On the other hand, among those diagnosed at 55years of age or older, NHB women had lower odds of initiating chemotherapy among those diagnosed with grade 1 disease (OR = 0.61, 95% CI: 0.37, 0.99) than NHW women.
Table3
Multivariable-adjusted odds ratios and 95% confidence intervals associating patient demographic, tumor characteristics with receipt of chemotherapy, and stratified by race and age among breast cancer patients with discretionary indication for chemotherapy in Georgia (2010–2017)
| Discretionary indication for chemotherapy (< 55years of age) | Discretionary indication for chemotherapy (≥ 55years of age) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Patient demographic and tumor characteristics | (N) | Overall OR (95% CI)a | Treatment (N, %) | Stratified Effects OR (95% CI)a | (N) | Overall OR (95% CI)a | Treatment (N, %) | Stratified Effects OR (95% CI)a | ||
| Overall | NHW | NHB | Overall | NHW | NHB | |||||
| Overall disparity | 1425 | 889 | 536 | 1.50 (1.28, 1.75) | 1447 | 1041 | 406 | 1.34 (1.17, 1.54) | ||
| Age at diagnosis | ||||||||||
| > 70 | 182 | 0.67 (0.53, 0.86) | 143 | 39 | 1.26 (0.88, 1.79) | |||||
| ≤ 70 | 1265 | Ref | 898 | 367 | 1.46 (1.27, 1.67) | |||||
| Stage | ||||||||||
| I | 818 | Ref | 531 | 287 | 1.40 (1.15, 1.70) | 899 | Ref | 671 | 228 | 1.22 (1.03, 1.45) |
| II | 607 | 3.20 (2.71, 3.77) | 358 | 249 | 1.40 (1.04, 1.88) | 548 | 3.50 (3.07, 4.00) | 370 | 178 | 1.36 (1.07, 1.73) |
| Tumor grade | ||||||||||
| 1 | 129 | Ref | 88 | 41 | 1.53 (0.99, 2.35) | 157 | Ref | 137 | 20 | 0.61 (0.37, 0.99) |
| 2 | 548 | 2.89 (2.31, 3.61) | 387 | 161 | 1.04 (0.75, 1.44) | 597 | 2.95 (2.44, 3.56) | 449 | 148 | 1.08 (0.85, 1.38) |
| 3 + | 723 | 13.9 (11.8, 17.9) | 396 | 327 | 0.97 (0.76, 1.24) | 672 | 12.1 (9.90, 14.8) | 441 | 231 | 1.12 (0.91, 1.39) |
| ODX testing | ||||||||||
| Testing not performed | 1098 | 0.91 (0.76, 1.08) | 652 | 446 | 1.58 (1.31, 1.90) | 1130 | 0.71 (0.61, 0.82) | 796 | 334 | 1.38 (1.18, 1.61) |
| Scored | 327 | Ref | 237 | 90 | 0.93 (0.66, 1.31) | 317 | Ref | 245 | 72 | 0.90 (0.65, 1.24) |
| Marital status | ||||||||||
| Single | 492 | 1.12 (0.96, 1.31) | 218 | 274 | 1.51 (1.22, 1.88) | 549 | 0.98 (0.86, 1.10) | 325 | 224 | 1.29 (1.06, 1.57) |
| Married | 875 | Ref | 642 | 233 | 1.39 (1.08, 1.79) | 847 | Ref | 682 | 165 | 1.50 (1.22, 1.84) |
| Socioeconomic Index | ||||||||||
| 0% – < 5% poverty | 206 | Ref | 168 | 38 | 2.50 (1.41, 2.09) | 205 | Ref | 171 | 34 | 2.30 (1.40, 3.76) |
| 5% – < 10% poverty | 286 | 0.90 (0.71, 1.15) | 209 | 77 | 1.27 (0.89, 1.81) | 311 | 1.03 (0.84, 1.27) | 249 | 62 | 1.80 (1.27, 2.56) |
| 10% – < 20% poverty | 512 | 1.29 (1.03, 1.61) | 305 | 207 | 1.33 (1.02, 1.74) | 591 | 1.22 (1.01, 1.49) | 414 | 177 | 1.45 (1.15, 1.83) |
| 20–100% poverty | 421 | 1.56 (1.22, 2.01) | 207 | 214 | 1.29 (0.96, 1.75) | 479 | 1.21 (0.98, 1.49) | 291 | 188 | 1.03 (0.82, 1.30) |
| Urban/rural residence | ||||||||||
| Rural | 219 | 0.97 (0.77, 1.21) | 169 | 50 | 1.12 (0.68, 1.83) | 270 | 0.95 (0.81, 1.12) | 226 | 44 | 0.93 (0.64, 1.36) |
| Urban | 1206 | Ref | 720 | 486 | 1.35 (1.13, 1.62) | 1177 | Ref | 815 | 362 | 1.31 (1.12, 1.53) |
| Insurance type | ||||||||||
| Uninsured | 21 | 0.92 (0.49, 1.72) | 9 | 12 | 2.42 (0.67, 8.69) | 19 | 0.97 (0.56, 1.68) | 14 | 5 | 0.57 (0.16, 2.02) |
| Private | 1150 | Ref | 759 | 391 | 1.41 (0.76, 2.61) | 746 | Ref | 544 | 202 | 1.48 (1.20, 1.83) |
| Medicaid | 157 | 1.39 (1.05, 1.83) | 68 | 89 | 1.12 (0.67, 1.87) | 81 | 1.07 (0.80, 1.42) | 40 | 41 | 1.19 (0.69, 2.04) |
| Medicare | 36 | 0.65 (0.42, 1.01) | 18 | 18 | 1.96 (0.83, 4.64) | 548 | 0.99 (0.85, 1.17) | 408 | 140 | 1.27 (1.02, 1.59) |
| Military | 42 | 1.14 (0.72, 1.80) | 22 | 20 | 0.79 (0.32, 1.94) | 29 | 0.87 (0.58, 1.37) | 15 | 14 | 2.18 (0.91, 5.21) |
Open in a separate window
aAdjusted for: age, stage, grade, insurance status, poverty level, receipt of Oncotype DX, marital status, urban/rural status
In Table4 we present the racial disparities in breast cancer mortality by receipt of chemotherapy. Among those with discretionary indication for chemotherapy and who received chemotherapy, NHB women had 1.31 times the estimated mortality rate compared with NHW women (95% CI: 0.95, 1.81). Among those who did not receive chemotherapy, the disparity estimate was similar (HR = 1.41, 95% CI: 1.04, 1.91).
Table4
Hazard ratios (HR) and 95% confidence intervals (95% CI) associating chemotherapy receipt with breast cancer-specific mortality overall and by race among patients with discretionary indication for chemotherapy in Georgia (2010–2017)
| No. events | Racial disparity | |||
|---|---|---|---|---|
| NHW | NHB | HR (95%CI)a | HR (95%CI)b | |
| Discretionary for chemotherapy | ||||
| Chemotherapy | ||||
| Yes | 106 | 59 | 1.31 (0.95, 1.81) | 1.08 (0.77, 1.52) |
| No | 166 | 55 | 1.41 (1.04, 1.91) | 1.19 (0.85, 1.67) |
Open in a separate window
aAge-adjusted
bAdjusted for: age, stage, grade, insurance status, poverty level, node status, receipt of Oncotype DX, marital status, urban/rural
NHW non-Hispanic White, NHB non-Hispanic Black
In our sensitivity analyses among ER-positive breast cancer patients with limited lymph node involvement we observed comparable results (Supplemental Tables2, 3 and 4).
Discussion
In this study, we investigated differences in the initiation of chemotherapy across patient demographic and clinical characteristics among breast cancer patients diagnosed with ER-positive tumors who were considered to have a discretionary indication for chemotherapy per NCCN guidelines. We observed that NHB women were more likely, overall, to initiate chemotherapy than their NHW counterparts. However, this disparity was particularly pronounced among women diagnosed 70years or younger, with higher stage disease, patients who did not receive Oncotype DX testing, women living in high SES neighborhoods, and those with private insurance at the time of diagnosis. We did not observe racial disparities in the initiation of chemotherapy among women who received Oncotype DX testing, were diagnosed with grade 1 tumors, or among breast cancer patients residing in rural areas.
Few studies have investigated sociodemographic factors that impact chemotherapy initiation among patients with a discretionary chemotherapy indication [14, 23, 24]. Consistent with prior studies, we observed that patients diagnosed at age 70years or younger were more likely to initiate chemotherapy than those diagnosed over the age of 70. However, trials have indicated that age alone is insufficient to inform decisions regarding the initiation of chemotherapy [25]. In the current study, we did not have information regarding comorbid conditions present at diagnosis, which also influence the decision to initiate chemotherapy, especially among older breast cancer patients.
In our study, NHB women were more likely to initiate chemotherapy across nearly all patient demographic and clinical characteristics. This may indicate that NHB patients are being systematically over-treated with adjuvant chemotherapy when the indication is discretionary. We did not observe racial disparities in the initiation of chemotherapy among those who received Oncotype DX testing, suggesting that in the absence of following all clinical guidelines, NHB breast cancer patients are more likely to be over-treated with chemotherapy. Oncotype DX testing has led to biomarker-driven treatment among breast cancer patients that may contribute to more equitable care decisions in this group. We also did not observe racial disparities among those who resided in rural settings. The lack of disparities among those residing in rural settings may be driven by barriers in access to care for both NHB and NHW breast cancer patients, or due to providers being able to treat patients more equally as the patient volume is lower and there are more opportunities to bring patients to cancer centers [26]. Our results support the idea that when clinical guidelines are followed, patients receive the same recommended treatments, and overtreatment can be avoided.
We observed that NHB women had higher breast cancer mortality rates than NHW women, regardless of chemotherapy receipt. This may suggest that despite more aggressive treatment with chemotherapy among those with discretionary treatment indication, NHB women are still more likely to die from their disease. However, our estimates were imprecise due to a limited number of deaths due to breast cancer and additional studies with longer follow-up are needed. Further exploration of factors contributing to the differences in breast cancer mortality between Black and White women diagnosed with prognostically favorable tumors is necessary.
There are limitations to this study worth noting. First, we did not have information on functional status or comorbidities present at diagnosis, which would influence the decision-making process on whether to initiate chemotherapy. The risk of chemotherapy-related toxicities is higher among patients with low functional status or a high comorbidity burden, which would affect the oncologist’s willingness to proceed with chemotherapy among those with a discretionary indication. However, we expect that the comorbidity burden would be higher among NHB patients, and we did not observe lower chemotherapy initiation among NHB patients. Second, the time period of breast cancer diagnoses included in this cohort used Oncotype DX testing results prior to the results presented from the TAILORx and RxPONDER trials, which now guide chemotherapy guidelines [27]. Third, we did not consider tumor histology due to the low proportion in our sample with unfavorable tumor histologies. Future studies may want to consider tumor histology as well as breast cancer subtype as factors that influence chemotherapy receipt. Fourth, chemotherapy is often under ascertained by cancer registries and may suffer from misclassification. Finally, as this was a population-based registry study, we were unable to assess the decisions by the patient and physician to initiate chemotherapy, which would be informative for future work. Future studies would likely benefit from information regarding the decision-making process from patient and physician perspectives.
In this study, we observed differences by sociodemographic factors in the initiation of chemotherapy among breast cancer patients with a discretionary indication for chemotherapy. We also observed racial disparities in the initiation of chemotherapy overall and by sociodemographic factors. Overtreatment of chemotherapy may lead to an increase in adverse outcomes among breast cancer patients. Therefore, adherence to clinical guidelines can lead to equitable treatment among breast cancer patients. Further research may be warranted to understand potential adverse outcomes among NHB breast cancer patients who initiate chemotherapy when care is discretionary.
Supplementary Information
Below is the link to the electronic supplementary material.
Supplementary file1 (DOCX 30 KB)(30K, docx)
Author contributions
All authors contributed to the study conception and design. Material preparation, data collection and analysis were performed by LC, RN, and JS. The first draft of the manuscript was written by Lindsay Collin and all authors commented on previous versions of the manuscript. All authors read and approved the final manuscript.
Funding
This this work was supported, in part, by the Cancer Prevention and Control Research program, the Winship Research Informatics shared resources, a core supported by the Winship Cancer Institute of Emory University, and the Komen Foundation (CCR19608510) awarded to Lauren E McCullough. Lindsay J. Collin was supported by K99CA277580 from the National Cancer Institute of the National Institutes of Health. R Nash was supported by F31CA268737 from the National Cancer Institute of the National Institutes of Health. The collection of cancer incidence data used in this study was supported by contract HHSN261201800003I, Task Order HHSN26100001 from the NCI and cooperative agreement 5NU58DP003875-04 from the U.S. Centers for Disease Control and Prevention.
Data availability
The data are publicly available from the Georgia Cancer Registry, a cancer registry that is part of the Surveillance, Epidemiology, and End Results (SEER) program that provides information on cancer statistics in the United States.
Declarations
Competing interests
The authors declare no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. Ca Cancer J Clin. 2021;71:7–33. doi:10.3322/caac.21654. [PubMed] [CrossRef] [Google Scholar]
2. Guo F, Kuo Y, Shih YCT, Giordano SH, Berenson AB. Trends in breast cancer mortality by stage at diagnosis among young women in the United States. Cancer. 2018;124:3500–3509. doi:10.1002/cncr.31638. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
3. Giaquinto AN, Sung H, Miller KD, Kramer JL, Newman LA, Minihan A et al (2022) Breast cancer statistics, 2022. CA: A Cancer J Clin 72:524–541. 10.3322/caac.21754 [PubMed]
4. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA. 2006;295:2492–2502. doi:10.1001/jama.295.21.2492. [PubMed] [CrossRef] [Google Scholar]
5. Collin LJ, Yan M, Jiang R, Gogineni K, Subhedar P, Ward KC, et al (2021) Receipt of guideline-concordant care does not explain breast cancer mortality disparities by race in Metropolitan Atlanta. J Natl Compr Canc Netw: jnccn20258. 10.6004/jnccn.2020.7694 [PMC free article] [PubMed]
6. Gradishar WJ, Anderson BO, Balassanian R, Blair SL, Burstein HJ, Cyr A, et al. NCCN guidelines insights: breast cancer, Version 1.2017. J Natl Compr Canc Netw. 2017;15:433–51. doi:10.6004/jnccn.2017.0044. [PubMed] [CrossRef] [Google Scholar]
7. Aizer AA, Wilhite TJ, Chen M-H, Graham PL, Choueiri TK, Hoffman KE, et al. Lack of reduction in racial disparities in cancer-specific mortality over a 20-year period. Cancer. 2014;120:1532–1539. doi:10.1002/cncr.28617. [PubMed] [CrossRef] [Google Scholar]
8. DeSantis CE, Fedewa SA, Goding Sauer A, Kramer JL, Smith RA, Jemal A. Breast cancer statistics, 2015: convergence of incidence rates between black and white women. CA Cancer J Clin. 2016;66:31–42. doi:10.3322/caac.21320. [PubMed] [CrossRef] [Google Scholar]
9. DeSantis CE, Siegel RL, Sauer AG, Miller KD, Fedewa SA, Alcaraz KI et al (2016) Cancer statistics for African Americans, 2016: Progress and opportunities in reducing racial disparities. CA: A Cancer J Clin 66:290–308. 10.3322/caac.21340 [PubMed]
10. DeSantis CE, Ma J, Sauer AG, Newman LA, Jemal A (2017) Breast cancer statistics, 2017, racial disparity in mortality by state. CA: A Cancer J Clin 67:439. 10.3322/caac.21412 [PubMed]
11. Collin LJ, Jiang R, Ward KC, Gogineni K, Subhedar PD, Sherman ME, et al. Racial disparities in breast cancer outcomes in the metropolitan Atlanta area: new insights and approaches for health equity. JNCI Cancer Spectr. 2019;3:pkz053. doi:10.1093/jncics/pkz053. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
12. Zhang Y, Ye Q, He J, Chen P, Wan J, Li J, et al. Recurrence-associated multi-RNA signature to predict disease-free survival for ovarian cancer patients. Biomed Res Int. 2020;2020:1618527. doi:10.1155/2020/1618527. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Williams AD, Solis O, Sterbling HM, Murray A, Sogunro O, De La Cruz LM. Are we overtreating patients with T1a HER2+ breast cancer? An analysis of the national cancer database. Clin Breast Cancer. 2022 doi:10.1016/j.clbc.2022.07.013. [PubMed] [CrossRef] [Google Scholar]
14. Neugut AI, Hillyer GC, Kushi LH, Lamerato L, Leoce N, Nathanson SD, et al. Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol. 2012;30:3800–3809. doi:10.1200/JCO.2012.43.8168. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
15. Howe HL (2005) NAACCR guideline for enhancing Hispanic-Latino identification: revised NAACCR Hispanic/Latino identification algorithm [NHIA v2]
16. Carlson RW, Allred DC, Anderson BO, Burstein HJ, Carter WB, Edge SB, et al. Invasive breast cancer. J Natl Compr Canc Netw. 2011;9:136–222. doi:10.6004/jnccn.2011.0016. [PubMed] [CrossRef] [Google Scholar]
17. Knoble NB, Alderfer MA, Hossain MJ. Socioeconomic status (SES) and childhood acute myeloid leukemia (AML) mortality risk: analysis of SEER data. Cancer Epidemiol. 2016;44:101–108. doi:10.1016/j.canep.2016.07.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
18. Kish JK, Yu M, Percy-Laurry A, Altekruse SF. Racial and ethnic disparities in cancer survival by neighborhood socioeconomic status in surveillance, epidemiology, and end results (SEER) registries. J Natl Cancer Inst Monogr. 2014;2014:236–243. doi:10.1093/jncimonographs/lgu020. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
19. Bosco JLF, Silliman RA, Thwin SS, Geiger AM, Buist DSM, Prout MN, et al. A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies. J Clin Epidemiol. 2010;63:64–74. doi:10.1016/j.jclinepi.2009.03.001. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
20. Howards PP, Schisterman EF, Poole C, Kaufman JS, Weinberg CR. “Toward a clearer definition of confounding” revisited with directed acyclic graphs. Am J Epidemiol. 2012;176:506–511. doi:10.1093/aje/kws127. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Lash TL. The harm done to reproducibility by the culture of null hypothesis significance testing. Am J Epidemiol. 2017;186:627–635. doi:10.1093/aje/kwx261. [PubMed] [CrossRef] [Google Scholar]
22. Wasserstein RL, Lazar NA. The ASA statement on p-values: context, process, and purpose. Am Stat. 2016;70:129–133. doi:10.1080/00031305.2016.1154108. [CrossRef] [Google Scholar]
23. Greenlee H, Neugut AI, Falci L, Hillyer GC, Buono D, Mandelblatt JS, et al. Association between complementary and alternative medicine use and breast cancer chemotherapy initiation: the breast cancer quality of care (BQUAL) study. JAMA Oncol. 2016;2:1170–1176. doi:10.1001/jamaoncol.2016.0685. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. Wu X-C, Lund MJ, Kimmick GG, Richardson LC, Sabatino SA, Chen VW, et al. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers. J Clin Oncol. 2012;30:142–150. doi:10.1200/JCO.2011.36.8399. [PubMed] [CrossRef] [Google Scholar]
25. Muss HB, Berry DA, Cirrincione C, Budman DR, Henderson IC, Citron ML, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B experience. J Clin Oncol. 2007;25:3699–3704. doi:10.1200/JCO.2007.10.9710. [PubMed] [CrossRef] [Google Scholar]
26. Lipscomb J, Gillespie TW, Goodman M, Richardson LC, Pollack LA, Ryerson AB, et al. Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US. Breast Cancer Res Treat. 2012;133:285–296. doi:10.1007/s10549-011-1916-1. [PMC free article] [PubMed] [CrossRef] [Google Scholar]
27. Sparano JA, Gray RJ, Wood WC, Makower DF, Lively TG, Saphner TJ, et al. TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score. JCO. 2018;36:LBA1. doi:10.1200/JCO.2018.36.18_suppl.LBA1. [CrossRef] [Google Scholar]
Articles from Breast Cancer Research and Treatment are provided here courtesy of Springer
